Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia.

abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

journal_title：Prostate cancer and prostatic diseases

authors： Potters L,Fearn P,Kattan M

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

journal_title：Prostate cancer and prostatic diseases

authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

更新日期：2020-12-01 00:00:00

abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...

journal_title：Prostate cancer and prostatic diseases

authors： Sadetsky N,Elkin EP,Latini DM,DuChane J,Carroll PR,CaPSURE Investigators.

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...

journal_title：Prostate cancer and prostatic diseases

authors： Dall'Era MA,Klotz L

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...

journal_title：Prostate cancer and prostatic diseases

authors： Jamnagerwalla J,Howard LE,Allott EH,Vidal AC,Moreira DM,Castro-Santamaria R,Andriole GL,Freeman MR,Freedland SJ

更新日期：2018-06-01 00:00:00

abstract：:Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...

journal_title：Prostate cancer and prostatic diseases

authors： Klein EA,Thompson IM,Lippman SM,Goodman PJ,Albanes D,Taylor PR,Coltman C

更新日期：2000-11-01 00:00:00

abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

journal_title：Prostate cancer and prostatic diseases

authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

更新日期：2020-09-01 00:00:00

abstract：:Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treat...

journal_title：Prostate cancer and prostatic diseases

authors： Tomic R,Ljungberg B

更新日期：1999-07-01 00:00:00

abstract：BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

journal_title：Prostate cancer and prostatic diseases

authors： Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

更新日期：2012-03-01 00:00:00

abstract：:The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary continence and erectile function in patients undergoing radical prostatectomy (RP). We included 257 patients with clinically localized prostate cancer, those who had filled out preoperative quality of life questionnaires (...

journal_title：Prostate cancer and prostatic diseases

authors： Gacci M,Corona G,Apolone G,Lanciotti M,Tosi N,Giancane S,Masieri L,Serni S,Maggi M,Carini M

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...

journal_title：Prostate cancer and prostatic diseases

authors： Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo J

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and c...

journal_title：Prostate cancer and prostatic diseases

authors： Werneburg GT,Kongnyuy M,Halpern DM,Salcedo JM,Kosinski KE,Haas JA,Schiff JT,Corcoran AT,Katz AE

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...

journal_title：Prostate cancer and prostatic diseases

authors： Mano R,Eastham J,Yossepowitch O

更新日期：2016-12-01 00:00:00

abstract：:An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe w...

journal_title：Prostate cancer and prostatic diseases

authors： Ross AE,D'Amico AV,Freedland SJ

更新日期：2016-03-01 00:00:00

abstract：:This study provides further insights into those preoperative parameters that predict side-specific risk of pathological stage in men undergoing radical prostatectomy (RP). The transrectal ultrasound-guided tissue biopsy cores obtained from the right and left sides of the prostate were collected in separate jars and ex...

journal_title：Prostate cancer and prostatic diseases

authors： Sankin A,Tareen B,Lepor H

更新日期：2009-01-01 00:00:00

abstract：:We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group...

journal_title：Prostate cancer and prostatic diseases

authors： Egawa S,Okusa H,Matsumoto K,Suyama K,Baba S

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS:Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43-69, mean 64 years). Patients with a c...

journal_title：Prostate cancer and prostatic diseases

authors： Latifoltojar A,Dikaios N,Ridout A,Moore C,Illing R,Kirkham A,Taylor S,Halligan S,Atkinson D,Allen C,Emberton M,Punwani S

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

journal_title：Prostate cancer and prostatic diseases

authors： Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

更新日期：2012-06-01 00:00:00

abstract：:Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expect...

journal_title：Prostate cancer and prostatic diseases

authors： Gómez-Sancha F

更新日期：1999-12-01 00:00:00

abstract：PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

journal_title：Prostate cancer and prostatic diseases

authors： Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

更新日期：2003-01-01 00:00:00

abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

更新日期：2009-01-01 00:00:00

abstract：:Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...

journal_title：Prostate cancer and prostatic diseases

authors： Choi HY,Lim JE,Hong JH

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

journal_title：Prostate cancer and prostatic diseases

authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Accumulating evidence suggests that obesity is associated with tumor progression in prostate cancer (PCa) patients after radical prostatectomy (RP). We conducted a retrospective multicenter study to determine the effect of body mass index (BMI) on the clinicopathological characteristics and biochemical recur...

journal_title：Prostate cancer and prostatic diseases

authors： Narita S,Mitsuzuka K,Yoneyama T,Tsuchiya N,Koie T,Kakoi N,Kawamura S,Kaiho Y,Ohyama C,Tochigi T,Yamaguchi T,Habuchi T,Arai Y

更新日期：2013-09-01 00:00:00

abstract：:The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...

journal_title：Prostate cancer and prostatic diseases

authors： Vallancien G,Pariente P

更新日期：2001-01-01 00:00:00

abstract：:The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will briefly review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we wi...

journal_title：Prostate cancer and prostatic diseases

authors： McEleny KR,Watson RW,Fitzpatrick JM

更新日期：2001-01-01 00:00:00

abstract：:The present study seeks to establish a relationship between the quality of a surgical procedure and the subsequent hospital costs for that procedure by investigating the influence of both patient and peri-operative factors on the hospital costs of radical prostatectomy. All men who underwent radical prostatectomy at o...

journal_title：Prostate cancer and prostatic diseases

authors： Benoit RM,Cohen JK

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

journal_title：Prostate cancer and prostatic diseases

authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

journal_title：Prostate cancer and prostatic diseases

authors： Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

更新日期：2016-12-01 00:00:00

abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

journal_title：Prostate cancer and prostatic diseases

authors： Gould DC,Kirby RS

更新日期：2006-01-01 00:00:00